Clinical Research Directory

Inclusion Criteria: * Males or females, age 18 to \<81 years at the time of consent * Biopsy-proven peritoneal carcinomatosis * Documented receipt of at least three months of standard systemic chemotherapy prior to initiation, with persistent disease * ECOG Performance Status of 0 or 1 * Adequate organ function within 14 days prior to anti-fibrotic initiation * Negative serum pregnancy test for women of childbearing potential (WOCBP) within 7 days prior to initiation * Able to understand and provide written informed consent * Willingness and ability to comply with all study procedures Exclusion Criteria: * Patients deemed eligible for definitive cytoreductive surgery * Current or recent (within 30 days) use of paricalcitol, pirfenidone, or Vitamin D supplementation above USDA-recommended daily dosage * Known allergy or medical contraindication to study drugs * Hypersensitivity to any of the study drugs or to any ingredient in the formulation * Receipt of any investigational drug within 30 days prior to initiation * Active pregnancy or lactation * Active smoking * Active brain metastases * Elevated Vitamin D level (\>2x upper limit of normal) * Significant comorbidities including abnormal calcium/phosphate, history of serious drug-induced liver injury, severe cardiac conditions, patients with or predisposed to cardiac arrhythmias, or uncontrolled hypertension * Concomitant medications that, after review by the study pharmacist(s) and potential dose modification in accordance with prescribing guidelines, still pose an unmanageable drug-drug interaction or unacceptable safety risk with either study drug